The loss of gut microbiota-derived bile salt hydrolases predisposes to CDI. @bhmullish & colleagues showed restoration of gut BSH functionality contributes to the efficacy of FMT in treating rCDI based on a paper in @Gut_BMJ @esnm_eu #GMFHCoverage pic.twitter.com/0jeZAkk7Ax— GutMicrobiota Health (@GMFHx) November 22, 2022

Blount: As microbiome is considered a new organ in the scientific and medical arena, there is an ongoing debate on whether fecal microbiota transplant is a drug or an organ@esnm_eu #GMFHCoverage pic.twitter.com/x9UM5e9PdE— GutMicrobiota Health (@GMFHx) November 22, 2022

The design of clinical trials is relevant for ensuring reproducibility of microbiota-based therapeutics. Blount now shares the pipeline of RBX2660 for reducing recurrent C. difficile infection @Rebiotix @FerringMBiome @esnm_eu #GMFHCoverage pic.twitter.com/4QlKcJrYy6— GutMicrobiota Health (@GMFHx) November 22, 2022

According to Blount, microbiome changes are relevant in explaining the efficacy of RBX2660. High engraftment persisted to at least 6 months after study treatment @esnm_eu #GMFHCoverage pic.twitter.com/rX4sRcbZLe— GutMicrobiota Health (@GMFHx) November 22, 2022

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,...

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

What is the potential of microbiome-based medicine in the era of precision management? This special issue in @AGA_Gastro is still timely and includes interesting readings in the field, such as major caveats in defining a healthy microbiome: https://t.co/PdjimGbLnz pic.twitter.com/zAUPBCD9x4— GutMicrobiota Health (@GMFHx) November 19, 2022

C Difficile Infection Drug Market 2022 Forecast to 2029 research provides accurate economic global and country level predictions and analyses It provides a comprehensive perspective of the competitive market as well as an in depth supply chain analysis to assist ...

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

The CDi-screen is suitable for studying C. difficile proliferation in a complex gut ecosystem and for screening for anti-pathogenic interventions that target C. difficile directly and/or indirectly through interactions with the gut microbiota. Different doses of compounds such as in th …

/PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10...

– Investigational oral microbiome therapeutic was observed to reduce recurrent C. difficile infection (rCDI) after just one recurrence and remained low regardless of diagnostic approach –– Clinical data shows SER-109 is well tolerated, including among people with multiple comorbidities –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeuti..

DBMR team makes use of simple language and easy to understand statistical images to provide thorough information and in-depth data on

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, tod

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

Join us as part of the John G. Bartlett Memorial Education Series, in honor of Clostridioides difficile (C. diff) Awareness Month, which is an effort to brin...

SER-109, an investigational oral microbiome therapeutic, was well-tolerated and durably reduced rates of recurrent Clostridioides difficile infection through 24 weeks, with benefits showing as early as week 2, data show. SER-109 (Seres Therapeutics) is an oral capsule prepared from healthy donor stool containing dormant Firmicute spores that are activated in the lower GI tract. It received orphan

Clostridioides difficile Infection (CDI) is a bacterial infection of  the large intestine (colon).  A spectrum of clinical disease ranges from...

NTCD-M3 for Clostridioides difficile Infections (CDI) Professor Mark Wilcox presents at the Destiny Pharma R&D Investor Update meeting – 18th October 2022 Professor Dale Gerding discusses the threat of C. difficile infections NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. It is an

.@VedantaBio is a biopharma company pioneering the development of defined bacterial consortia as oral therapies to modulate the #microbiome to treat disease. Its pipeline includes product candidates for #CDiff, #IBD, Gram-negative infections & tumors. https://t.co/zhKTMiqZ73— MTIG (@MTIG_News) November 11, 2022

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...

A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …

Fruits such as apples are a dietary source of polyphenols and have health benefits. We studied the benefits of apple polyphenols in reducing intestinal infections. We explored the potential roles of apple polyphenols in combating Clostridioides difficile-induced intestinal infections by modul …

MICROBIOME MEDICINE - Imperial is partnering with biotechnology company EnteroBiotix on research into the potential of therapies based on the gut bacterial community.

A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …